Lv53
810 积分 2024-12-16 加入
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
1天前
已完结
Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial
2天前
已完结
Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
3个月前
已完结
新型抗肿瘤药物在EGFR-TKI耐药非小细胞肺癌中的研究进展
3个月前
已完结
Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives
3个月前
已完结
Top product forecasts for 2025
6个月前
已完结
皖公网安备34019202002308
